59.95 USD
-0.21 (-0.35%)
59.95 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 82% to BMRN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 92.08. This target is 53.59% above the current price.
BMRN was analyzed by 34 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about BMRN.
In the previous month the buy percentage consensus was at a similar level.
BMRN was analyzed by 34 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-23 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-22 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-12-03 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-11-06 | Stifel | Downgrade | Buy -> Hold |
| 2025-11-03 | Bernstein | Maintains | Outperform -> Outperform |
| 2025-10-28 | Stifel | Maintains | Buy -> Buy |
| 2025-10-28 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-28 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-28 | Truist Securities | Maintains | Buy -> Buy |
| 2025-10-28 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-27 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-10-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-08 | HC Wainwright & Co. | Initiate | Neutral |
| 2025-08-06 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-05 | UBS | Maintains | Buy -> Buy |
| 2025-07-22 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-05 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-05-02 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-02-24 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-02-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-02-20 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-02-20 | UBS | Maintains | Buy -> Buy |
| 2025-02-20 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-02-20 | B of A Securities | Maintains | Buy -> Buy |
| 2025-02-20 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-20 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-12-12 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-15 | Wolfe Research | Initiate | Outperform |
| 2024-10-30 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
What do analysts expect the price target to be for BIOMARIN PHARMACEUTICAL INC (BMRN)?
34 analysts have analysed BMRN and the average price target is 92.08 USD. This implies a price increase of 53.59% is expected in the next year compared to the current price of 59.95.
How do analysts rate BIOMARIN PHARMACEUTICAL INC (BMRN)?
The consensus rating for BIOMARIN PHARMACEUTICAL INC (BMRN) is 82.3529 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for BMRN stock?
The number of analysts covering BIOMARIN PHARMACEUTICAL INC (BMRN) is 34.